{Reference Type}: Case Reports
{Title}: Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report.
{Author}: Wang J;Shen SH;Hu BF;Wang GL;
{Journal}: Medicine (Baltimore)
{Volume}: 100
{Issue}: 25
{Year}: Jun 2021 25
{Factor}: 1.817
{DOI}: 10.1097/MD.0000000000026440
{Abstract}: <B>BACKGROUND: </B>Relapsed or refractory acute lymphoblastic leukemia poses a significant clinical challenge due to its poor prognosis, showing survival rates of less than a year even with the use of novel therapies. In this report, we describe the safe and effective use of trametinib combined with dasatinib in a patient with acute lymphoblastic leukemia (ALL). To the best of our knowledge, this is the first report on the successful use of 2 targeted drugs such as trametinib and dasatinib in a pediatric patient with Ph+ ALL and recurrent pancreatitis.<BR><B>METHODS: </B>A 6-year-old boy with ALL and Philadelphia chromosome (Ph+) who had recurrent asparaginase-associated pancreatitis.<BR><B>METHODS: </B>The patient was diagnosed with ALL, based on clinical features, laboratory analyses, bone marrow aspiration evaluation in morphology, immunology, cytogenetics, and molecular.<BR><B>METHODS: </B>The patient was treated with dasatinib combined with an intermediate risk-oriented chemotherapy. However, owing to recurrent asparaginase-associated pancreatitis, the patient has to abandon asparaginase in consolidation. Considering the high risk of relapse, we used trametinib and dasatinib combined with chemotherapy as maintenance chemotherapy.<BR><B>RESULTS: </B>After 6 months, there were no obvious side effects or residual disease.<BR><B>CONCLUSIONS: </B>We suggest that the combination of trametinib and dasatinib may represent a viable option to treat patients with potential relapsed/refractory Ph+ ALL.